XENIOS AG, a commercial -stage medical device company, announced today that it has received a significant cash infusion from existing investors. While the amount of investment was not disclosed, it was in the eight-figures range, led by ZFHN, which typically invests up to 10 million euros in any given transaction.
XENIOS is the recognized technology leader in minimally invasive medical devices that unite one console, XENIOS, with next-generation lung (novalung) and heart ( i -cor) therapies into a single platform for a market with revenue potential of nearly $9 billion.
“No other company except Xenios is offering minimally invasive disposable lung and heart therapies on one platform,” said Georg Matheis, MD, Managing Director of XENIOS. “The XENIOS platform provides fundamental advantages with its minimally invasive lung and heart therapies. Patients are awake and mobile. Self-determined patients facilitate improved outcomes. There is no ventilator-associated lung injury and pneumonia. Additionally, the XENIOS platform maintains a physiologic natural pulse designed to protect the heart.
“This significant cash infusion empowers us to expand sales of our leading products in a highly profitable yet under-penetrated market,” said Dr. Matheis. “The XENIOS strategy is to build a highly profitable business in the US and Europe with upside potential in Asia. Our company is generating considerable revenues with a scalable business, direct sales in place in three EU countries, and global KOLs in place as product champions. XENIOS has clinically proven applications of its therapies with predictable execution. Regulatory approvals are in place (CE-marked, some products FDAcleared, plus several Asian markets). And we are extremely proud that XENIOS w i l l b e p r o fitable from operations in 2015,” concluded Dr. Matheis.
XENIOS is the recognized technology leader in minimally invasive medical devices that unite one console, XENIOS, with next-generation lung (novalung) and heart ( i -cor) therapies into a single platform for a market with revenue potential of nearly $9 billion.
“No other company except Xenios is offering minimally invasive disposable lung and heart therapies on one platform,” said Georg Matheis, MD, Managing Director of XENIOS. “The XENIOS platform provides fundamental advantages with its minimally invasive lung and heart therapies. Patients are awake and mobile. Self-determined patients facilitate improved outcomes. There is no ventilator-associated lung injury and pneumonia. Additionally, the XENIOS platform maintains a physiologic natural pulse designed to protect the heart.
“This significant cash infusion empowers us to expand sales of our leading products in a highly profitable yet under-penetrated market,” said Dr. Matheis. “The XENIOS strategy is to build a highly profitable business in the US and Europe with upside potential in Asia. Our company is generating considerable revenues with a scalable business, direct sales in place in three EU countries, and global KOLs in place as product champions. XENIOS has clinically proven applications of its therapies with predictable execution. Regulatory approvals are in place (CE-marked, some products FDAcleared, plus several Asian markets). And we are extremely proud that XENIOS w i l l b e p r o fitable from operations in 2015,” concluded Dr. Matheis.
